$477 Million is the total value of GREAT POINT PARTNERS LLC's 30 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 78.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MGNX | Buy | MACROGENICS INC | $37,026,000 | -13.9% | 1,378,495 | +2.1% | 7.77% | -12.6% |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $36,187,000 | +7.3% | 817,040 | +7.5% | 7.59% | +8.9% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $34,487,000 | +32.2% | 505,670 | +34.5% | 7.23% | +34.2% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $31,649,000 | +21.0% | 176,406 | +12.8% | 6.64% | +22.8% |
| PODD | Buy | INSULET CORP | $28,714,000 | +22.8% | 104,600 | +16.7% | 6.02% | +24.6% |
| EXEL | Buy | EXELIXIS INC | $25,401,000 | -6.4% | 1,394,107 | +16.1% | 5.33% | -5.0% |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $20,364,000 | -0.2% | 861,410 | 0.0% | 4.27% | +1.3% | |
| KDMN | Buy | KADMON HLDGS INC | $18,692,000 | +1.1% | 4,830,000 | +1.6% | 3.92% | +2.6% |
| NTLA | New | INTELLIA THERAPEUTICS INCcall | $16,191,000 | – | 100,000 | +100.0% | 3.40% | – |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $16,153,000 | -30.2% | 100,000 | -25.9% | 3.39% | -29.1% |
| TVTX | Buy | TRAVERE THERAPEUTICS INC | $15,820,000 | +6.7% | 1,084,300 | +82.6% | 3.32% | +8.3% |
| FOLD | New | AMICUS THERAPEUTICS INC | $15,424,000 | – | 1,600,000 | +100.0% | 3.24% | – |
| SAGE | Sell | SAGE THERAPEUTICS INC | $14,203,000 | -50.3% | 250,000 | -34.6% | 2.98% | -49.6% |
| DYN | New | DYNE THERAPEUTICS INC | $14,151,000 | – | 672,559 | +100.0% | 2.97% | – |
| RPTX | New | REPARE THERAPEUTICS INC | $13,597,000 | – | 436,089 | +100.0% | 2.85% | – |
| FGEN | New | FIBROGEN INCcall | $13,315,000 | – | 500,000 | +100.0% | 2.79% | – |
| OCUL | Sell | OCULAR THERAPEUTIX INC | $13,044,000 | -21.1% | 919,887 | -8.7% | 2.74% | -19.9% |
| XENT | Sell | INTERSECT ENT INC | $11,963,000 | -57.0% | 700,000 | -47.5% | 2.51% | -56.4% |
| PBYI | PUMA BIOTECHNOLOGY INC | $11,934,000 | -5.6% | 1,300,000 | 0.0% | 2.50% | -4.2% | |
| BIIB | Sell | BIOGEN INC | $11,254,000 | -46.4% | 32,500 | -56.7% | 2.36% | -45.5% |
| MGTA | New | MAGENTA THERAPEUTICS INC | $10,867,000 | – | 1,111,111 | +100.0% | 2.28% | – |
| KURA | New | KURA ONCOLOGY INC | $10,425,000 | – | 500,000 | +100.0% | 2.19% | – |
| ANAB | New | ANAPTYSBIO INC | $10,373,000 | – | 400,051 | +100.0% | 2.18% | – |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $9,208,000 | – | 329,086 | +100.0% | 1.93% | – |
| TCDA | Buy | TRICIDA INC | $8,528,000 | +361.2% | 1,974,000 | +464.6% | 1.79% | +368.3% |
| IFRX | INFLARX NV | $6,534,000 | -23.8% | 2,200,000 | 0.0% | 1.37% | -22.7% | |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $6,510,000 | – | 1,500,000 | +100.0% | 1.37% | – |
| CTMX | New | CYTOMX THERAPEUTICS INC | $6,330,000 | – | 1,000,000 | +100.0% | 1.33% | – |
| AGLE | Buy | AEGLEA BIOTHERAPEUTICS INC | $6,264,000 | +57.3% | 900,000 | +79.0% | 1.31% | +59.7% |
| VERV | New | VERVE THERAPEUTICS INC | $2,109,000 | – | 35,000 | +100.0% | 0.44% | – |
| GERN | Exit | GERON CORP | $0 | – | -2,610,000 | -100.0% | -0.85% | – |
| YMAB | Exit | Y-MABS THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -0.94% | – |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -250,000 | -100.0% | -0.94% | – |
| RDHL | Exit | REDHILL BIOPHARMA LTDsponsored ads | $0 | – | -705,305 | -100.0% | -1.07% | – |
| LUNG | Exit | PULMONX CORP | $0 | – | -114,345 | -100.0% | -1.08% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -311,217 | -100.0% | -1.66% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -80,000 | -100.0% | -2.31% | – |
| LNTH | Exit | LANTHEUS HLDGS INC | $0 | – | -649,516 | -100.0% | -2.87% | – |
| CNST | Exit | CONSTELLATION PHARMCETICLS I | $0 | – | -872,415 | -100.0% | -4.22% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -930,000 | -100.0% | -6.08% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.